Preliminary evaluation of the effectiveness of autologous bone marrow stem cell therapy in supporting the treatment of biliary atresia
Nội dung chính của bài viết
Tóm tắt
Biliary atresia (BA) is a rare hepatobiliary disorder. Stem cell therapy is expected to serve as a supportive treatment to slow fibrosis progression. This study aimed to assess the therapeutic efficacy and the safety of the Kasai procedure combined with autologous bone marrow stem cell (ABMSC) infusion. From May 2021 to December 2024, 82 pediatric BA patientswho underwent the combined treatment at Vietnam National Children’s Hospital were enrolled. The mean age at surgery was 76.8 ± 12.6 days. No severe complication occurred during stem cell harvesting or follow-up time frame. The successful bile drainage rate at 6 months post-surgery was 58.5%. Post-operatively, transaminase levels gradually declined and stabilized from 12 months. GGT levels peaked at 3 months (p < 0.001), then declined from 6 months and stayed stabilized. PELD scores improved significantly. Liver tissue elasticity increased gradually until 12 months (14.6 ± 4.5kPa) and then stabilized. Mean post-surgical survival was 34.3 ± 1.7 months, and 30-month survival rate was 64.7%. Portal hypertension occurred in 55% of patients, mostly in those with high-dose MSC therapy. Despite benefits achieved in liver function improvement, progressive cirrhosis remains a challenge, necessitating further research on optimizing stem cell therapy in BA treatment.
Chi tiết bài viết
Từ khóa
Biliary atresia, Kasai operation, autologous bone marrow stem cells, treatment outcomes, safety
Tài liệu tham khảo
2. Sonoda S, Yoshimaru K, Yamaza H, et al. Biliary atresia-specific deciduous pulp stem cells feature biliary deficiency. Stem Cell Research & Therapy. 2021;12(1):582. doi:10.1186/s13287-021-02652-8
3. Shi M, Li YY, Xu RN, et al. Mesenchymal stem cell therapy in decompensated liver cirrhosis: a long-term follow-up analysis of the randomized controlled clinical trial. Hepatol Int. 2021;15(6):1431-1441. doi:10.1007/s12072-021-10199-2
4. Kang SH, Kim MY, Eom YW, et al. Mesenchymal Stem Cells for the Treatment of Liver Disease: Present and Perspectives. Gut and Liver. 2020;14(3):306-315. doi:10.5009/gnl18412
5. Jasim SA, Yumashev AV, Abdelbasset WK, et al. Shining the light on clinical application of mesenchymal stem cell therapy in autoimmune diseases. Stem Cell Research & Therapy. 2022;13(1):101. doi:10.1186/s13287-022-02782-7
6. Gutierrez JV, Johnson L, Desai K, et al. Timing of Kasai Procedure for Biliary Atresia: An Analysis of the Pediatric National Surgical Quality Improvement Program Database. J Surg Res. 2024;301:681-685. doi:10.1016/j.jss.2024.07.002
7. Nafiu OO, Voepel-Lewis T, Morris M, et al. How do pediatric anesthesiologists define intraoperative hypotension? Paediatr Anaesth. 2009;19(11):1048-1053. doi:10.1111/j.1460-9592.2009.03140.x
8. Gad EH, Kamel Y, Salem TAH, et al. Short- and long-term outcomes after Kasai operation for type III biliary atresia: Twenty years of experience in a single tertiary Egyptian center-A retrospective cohort study. Ann Med Surg (Lond). 2021;62:302-314. doi:10.1016/j.amsu.2021.01.052
9. Lo Anh T. Evaluation of Kasai Surgery Results in Children with Congenital Biliary Atresia. Residency Thesis. Ho Chi Minh City University of Medicine and Pharmacy; 2018.
10. Jin YX, Hu HQ, Zhang JC, et al. Mechanism of mesenchymal stem cells in liver regeneration: Insights and future directions. World J Stem Cells. 2024;16(9):842-845. doi:10.4252/wjsc.v16.i9.842
11. Zhang Z, Lin H, Shi M, et al. Human umbilical cord mesenchymal stem cells improve liver function and ascites in decompensated liver cirrhosis patients. J Gastroenterol Hepatol. 2012;27 Suppl 2:112-120. doi:10.1111/j.1440-1746.2011.07024.x
12. Sharma S, Kumar L, Mohanty S, et al. Bone marrow mononuclear stem cell infusion improves biochemical parameters and scintigraphy in infants with biliary atresia. Pediatr Surg Int. 2011;27(1):81-89. doi:10.1007/s00383-010-2712-4
13. Khan AA, Parveen N, Mahaboob VS, et al. Treatment of Crigler-Najjar Syndrome type 1 by hepatic progenitor cell transplantation: a simple procedure for management of hyperbilirubinemia. Transplant Proc. 2008;40(4):1148-1150. doi:10.1016/j.transproceed.2008.03.022
14. Lu W, Qu J, Yan L, et al. Efficacy and safety of mesenchymal stem cell therapy in liver cirrhosis: a systematic review and meta-analysis. Stem Cell Research & Therapy. 2023;14(1):301. doi:10.1186/s13287-023-03518-x
15. Lin B liang, Chen J feng, Qiu W hong, et al. Allogeneic bone marrow–derived mesenchymal stromal cells for hepatitis B virus–related acute-on-chronic liver failure: A randomized controlled trial. Hepatology. 2017;66(1):209. doi:10.1002/hep.29189
16. Qiao G, Li L, Cheng W, et al. Conditional probability of survival in patients with biliary atresia after Kasai portoenterostomy: a Chinese population-based study. J Pediatr Surg. 2015;50(8):1310-1315. doi:10.1016/j.jpedsurg.2015.03.062.